MeiraGTx Q2 2026: $160.7M Profit, Cash Runway to H2 2028, Oberland Capital Deal Details
MGTX has more than doubled off its 52-week low of $6.62 on light trading volume (0.3× avg).
Summary
MeiraGTx swung to a $160.7M Q2 profit on collaboration revenue, detailed the Oberland Capital financing, and extended cash runway into H2 2028.
Key Events · Earnings and Guidance · MGTX
-
Q2 Profit of $160.7M
Net income of $160.7 million for Q2 2026, compared to a $38.8 million loss in Q2 2025, driven by $204.6 million in license revenue from the Hologen collaboration and $66.8 million in deferred revenue recognition from the Janssen termination.
-
Cash Runway Extended to H2 2028
Cash, cash equivalents, and restricted cash totaled $145.4 million at June 30, 2026. Combined with the $25 million second royalty note purchase and $10 million equity investment in Q3 2026, plus the $95 million Hologen upfront payment, the company estimates funding into the second half of 2028.
-
Oberland Capital Financing Details
The Royalty Note Purchase Agreement provides up to $375 million in non-dilutive capital in exchange for capped royalties on AAV-AIPL1, AAV-hAQP1, and bota-vec. The initial $100 million was funded on June 30, 2026, with an additional $25 million on July 17, 2026. A separate Securities Purchase Agreement provided $10 million in equity at $10.52 per share.
-
Hologen Collaboration Initial Closing
The Hologen strategic collaboration completed its initial closing in April 2026. MeiraGTx recognized a 39% equity interest in Reogen and recorded $204.6 million in license revenue. Hologen will fund an additional $95 million, bringing its total upfront commitment to $200 million.
Analysis · MGTX · Life Sciences
A $160.7 million Q2 profit marks a dramatic swing from the $38.8 million loss a year ago, driven by $204.6 million in license revenue from the Hologen collaboration and $66.8 million in deferred revenue recognition from the Janssen termination. The 10-Q also details the Oberland Capital royalty note financing (up to $375 million) and the $10 million equity investment, extending cash runway into the second half of 2028. The company's accumulated deficit remains $701.8 million, and management cautions that profitability was driven by non-recurring transactions.
At the time of this filing, MGTX was trading at $13.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $6.62 to $15.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.